Thanks to next-generation sequencing technologies, more recurrent somatic mutations in genes such as TP53, IDH1, IDH2, RUNX1, and ASXL1 have been found to have prognostic value in AML and affect treatment decisions [93,94]. The gene discussed is TP53; the disease is acute myeloid leukemia.